US Patent

US10864274 — Stabilized efinaconazole formulations

Method of Use · Assigned to Bausch Health Ireland Ltd · Expires 2034-10-02 · 8y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects stabilized formulations of efinaconazole, a drug used to treat fungal infections, that exhibit stable color profiles.

USPTO Abstract

The present invention provides compositions containing efinaconazole, butylated hydroxytoluene, a salt of ethylenediaminetetraacetic acid, and optional citric acid. The compositions exhibit stable color profiles and are useful in the treatment of fungal infections.

Drugs covered by this patent

Jublia (EFINACONAZOLE) · Bausch Health

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2720`	—	Jublia

Patent Metadata

Patent number: US10864274
Jurisdiction: US
Classification: Method of Use
Expires: 2034-10-02
Drug substance claim: No
Drug product claim: No
Assignee: Bausch Health Ireland Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.